[T-cell immunity against autologous leukemic cell mediated by in vitro bone marrow-derived dendritic cell from patients with acute myeloid leukemia in complete remission].
OBJECTIVE
To explore if a specific cytolytic T lymphocyte (CTL) response could be in vitro generated by using autogenous-leukemic cells lysates (ACL) pulsed dendritic cells ( DCs ) from AML-CR patients.


METHODS
T-cell depleted bone marrow mononuclear cells (TD-BMNC) were isolated from AML-CR patients with E-rosetting procedure, and then were cultured in vitro in the presence of combined cytokines ( GM-CSF, IL-4, SCF/TNF-alpha) for generation of mature DCs, and pulsed with ACL on day 5. After 7-day culture, the cells were harvested and the expression of mature DC marker was determined by FACS. For generation of a specific CTL to the respective AML cells, the cells were co-cultured with pre-activated auto-T lymphocytes by McAb anti-CD3 in the presence of low concentration of IL-2 for 7 days. Cytotoxicity was determined with LDH release.


RESULTS
Cultured TD-BMNCs from 12 AML-CR patients developed morphologic and phenotypic characteristics of mature DCs. CTL assay was performed in 6 out of the 12 samples. At effector/target ratio of 20:1, auto-T lymphocytes primed with ACL pulsed DC exhibited significant killing activity to auto-AML cells but not to K562 cells as compared with that stimulated by IL-2 alone or primed by non-pulsed DC (P = 0.001).


CONCLUSIONS
AML cell associated antigen specific CTL responses can be in vitro generated by priming auto-T lymphocytes with ACL pulsed DCs. These findings might prove useful for immunotherapy of AML.
He
X
X
The State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital , CAMS and PUMC, Tianjin 300020, China.
You
S
S
Bian
S
S
D000293:Adolescent; D000328:Adult; D001854:Bone Marrow Cells / Q000166:cytology*; D002648:Child; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology